April 23rd 2024
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Shortened Adjuvant Treatment Duration Reduced Toxicity Without Impacting Efficacy in Colon Cancer
November 9th 2022For patients with colon cancer, 3-month treatment with mFOLFOX6 or CAPOX improved safety outcomes without affecting efficacy vs 6-month treatment, according to data from the phase 3 ACHIEVE trial.
Trifluridine/Tipiracil Plus Bevacizumab Reaches Survival Endpoint in mCRC
October 11th 2022Data from the phase 3 SUNLIGHT study highlighted the increased survival benefit of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil alone for the treatment of metastatic colorectal cancer.
FDA Grants Priority Review to Tucatinib Plus Trastuzumab for Previously Treated HER2+ Metastatic CRC
September 20th 2022Patients with previously treated, metastatic, HER2-positive colorectal cancer may benefit from treatment with tucatinib and trastuzumab, which was granted priority review by the FDA.
Christine Parseghian, MD, on Promise of EGFR Rechallenge Therapy in Certain Patients With mCRC
September 7th 2022At the 2022 ASCO Annual Meeting, Christine Parseghian, MD, reviewed results from a phase 2 trial assessing efficacy of panitumumab plus or minus trametinib in patients with RAS/BRAF wild-type colorectal cancer and compared EGFR rechallenge strategies with available agents in the third-line setting.
Neoadjuvant Chemo May Reduce Necessity of Invasive Surgeries in Early-Stage Rectal Cancer
September 1st 2022Three months of neoadjuvant chemotherapy may downstage early-stage rectal cancer and thereby reduce the need for total mesorectal excisions (TMEs), resulting in higher rates of organ preservation.